NEW YORK (GenomeWeb News) – Cypress Bioscience has acquired Cellatope's technology platform for diagnosing and monitoring autoimmune disorders, such as lupus, for up to $5 million.

San Diego-based Cypress said that the technology platform uses cell-bound complement activation products for diagnosis and monitoring of response to treatment. It was developed by researchers at the Lupus center for Excellence at the University of Pittsburgh to evaluate cell-bound fragments of activated complement proteins and their utility in diagnosis and monitoring of lupus patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.